Sarcopenic Obesity in the Elderly

NCT ID: NCT06083909

Last Updated: 2023-10-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 97 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-04-06
• Study Completion Date: 2023-05-08

Brief Summary

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Conditions

Sarcopenic Obesity; Diabetes

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

This study will include both male and females aged 65-85 years.

Exclusion Criteria

1. Lack capacity to consent for the study, or have moderate or severe cognitive impairment;

2. Have difficulty ambulating as evidenced by any one of the following:

1. Difficulty climbing 10 steps without resting;

2. Restricted to a wheelchair

3. Have difficulty performing basic activities of daily living;

4. Have had treatment for cancer in the prior 3 years;

5. Have history of cachexia;

6. Have a history of heart failure;

7. Have a permanent pacemaker in situ (due to magnetic resonance scanning);

8. Have an implanted cardioverter-defibrillator (ICD) in situ;

9. Have had myocardial infarction within the last 6 months;

10. Have any of the following chronic health conditions: peripheral arterial disease prostate cancer, rheumatoid arthritis, autoimmune myositis, chronic obstructive pulmonary disease, and asthma;

11. Are receiving therapy with corticosteroids or immunosuppressants.

12. Are taking direct insulin sensitizers (PPAR-gamma agonists, or thiazolidinediones).

• Minimum Eligible Age: 65 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Central Florida

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Muthu Periasamy, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Central Florida

Mariana Dangiolo, MD

Role: PRINCIPAL_INVESTIGATOR

University of Central Florida

Ali Rizvi, MD

Role: PRINCIPAL_INVESTIGATOR

University of Central Florida

Locations

University of Central Florida

Orlando, Florida, United States

Countries

United States

Other Identifiers

STUDY00003268

Identifier Type: -

Identifier Source: org_study_id